Hematology & Medical Oncology Fellowship - Research/Scholarly Activities
We enroll approximately 300 patients annually on NCI NCORP and pharmaceutical industry-sponsored clinical research trials. Our Precision Cancer Therapies Program concentrates on new drug development and Phase 1.
Fellows are expected to complete a clinical research project, perform a quality/performance improvement project, and publish case reports/literature reviews during their fellowship.
Funds are available for fellows to present their research at national meetings.
Current Fellow Research
COVID-19 in Relation to Hematological Events and Mortality in Subset of Inpatient Cancer Patients for the upcoming AACR Virtual Meeting: COVID-19 and Cancer, July 20-22, 2020.
Outcomes of patients with multiple myeloma with COVID-19 infection for the upcoming AACR Virtual Meeting: COVID-19 and Cancer, July 20-22, 2020.
Prostate cancer and COVID-19: Impact of hormonal therapy on severe outcomes for the upcoming AACR Virtual Meeting: COVID-19 and Cancer, July 20-22, 2020.
COVID-19 patients critically ill in ICU: How hematological parameters have changed during their stay at Ochsner Medical Center
Malignant Mesothelioma and Germline Heterozygous BAP1 Mutation in a Young Woman Presenting with Recurrent Pleural Effusions and Worsening Pneumothorax After Talk Pleurodesis. Accepted CHEST 2020.
Clinical characteristics and outcomes of patients with resectable, metastatic colorectal cancer treated with adjuvant FOLFIRI after progression on neoadjuvant FOLFOX ASCRS Accepted January 24, 2020.
Utilization of genomic mutational information in breast cancer patients.
Interest in adaptive immunotherapies, and immune-related toxicities in solid tumors.
Involvement in prospective clinical trial looking using regimen to augment standard immunotherapy in melanoma & genitourinary patients.
Retrospective study looking at rate of autoimmune flares & irAES in patients with a pre-existing history of autoimmune disease.
Retrospective study evaluating cumulative steroid doses in solid tumor patients who received immune checkpoint inhibitors, and corresponding response rates.
Retrospective study evaluating parameters contributing to morbidity and mortality in COVID+ patients with cancer.
HLA type impact on myeloma transplant outcomes
Stratify myeloma patients and process through which we take them to transplant
Stem cell harvesting protocol in patients undergoing autologous stem cell transplant.
Distress scores in oncology patients and subsequent interventions
Rate of c diff infection in neutropenic patients treated with cefepime